Physician profile
Christian Michael Price
NPI 1760101893
$4,183.91
in general payments reported to CMS, 2019-2025
38 companies · $1,535 in 2025
The $1,535 reported for 2025 was more than what 92% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $37.68 · 2023: $1,443 · 2024: $1,169 · 2025: $1,535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,796 · Education: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,796.25 |
| Education | $349.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $470.54 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.67 | 2023-2025 | Enhertu, Calquence, Imfinzi |
| Janssen Biotech, INC. | $363.96 | 2023-2025 | Talvey, Erleada, Tecvayli |
| Daiichi Sankyo INC. | $360.47 | 2023-2025 | Enhertu, Datroway, Vanflyta |
| Incyte Corporation | $342.70 | 2023-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $264.81 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $186.75 | 2022-2025 | |
| Genmab U.S., INC. | $161.48 | 2023-2025 | Tivdak |
| Genzyme Corporation | $161.21 | 2023 | |
| Gilead Sciences, INC. | $151.51 | 2023-2024 | Trodelvy |
| Merck Sharp & Dohme LLC | $144.05 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $118.50 | 2023-2024 | Alunbrig, Ninlaro, Fruzaqla |
| Mirati Therapeutics, INC. | $98.52 | 2023-2024 | Krazati |
| Sanofi-Aventis U.S. LLC | $96.00 | 2023 | |
| Pfizer INC. | $87.50 | 2025 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $86.46 | 2023-2025 | Cabometyx |
| Sobi, INC | $80.16 | 2025 | |
| Alexion Pharmaceuticals, INC. | $75.13 | 2023-2024 | Ultomiris |
| Astellas Pharma US INC | $69.99 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $67.10 | 2024-2025 | Opdualag, Krazati |
| Tempus Ai, INC | $43.58 | 2025 | Xt Cdx |
| Stemline Therapeutics INC. | $40.62 | 2025 | Orserdu |
| Genentech USA, INC. | $30.19 | 2023-2025 | Polivy, Lunsumio, Columvi |
| Sumitomo Pharma America, INC. | $29.04 | 2025 | Orgovyx |
| Caris Mpi, INC. | $25.03 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $24.44 | 2024 | |
| Novocure INC. | $21.45 | 2025 | Optune Lua (Novottf-200t) |
| Regeneron Healthcare Solutions, INC. | $21.01 | 2025 | Libtayo |
| Apellis Pharmaceuticals, INC. | $20.97 | 2023 | Empaveli |
| Amgen INC. | $19.88 | 2023 | Blincyto, Kyprolis |
| Abbvie INC. | $19.47 | 2024 | |
| Jazz Pharmaceuticals INC. | $19.46 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.77 | 2025 | Danziten |
| Taiho Oncology, INC. | $16.76 | 2023 | |
| Pharmacosmos Therapeutics INC. | $16.32 | 2025 | Monoferric |
| Deciphera Pharmaceuticals INC. | $15.28 | 2023 | Qinlock |
| Emd Serono, INC. | $14.75 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.38 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.